Deals channel feed – Endpoints News

Deals channel feed

Busy Amgen swings another deal, this time with RNA drugging player Arrakis for 'several billion'

4 years ago

A new AI startup has emerged, and Pfizer likes what it sees

4 years ago

Bristol Myers takes a swing at 'off-the-shelf' cell therapies in $150M cash licensing pact with Century

4 years ago

Bristol Myers to spend $50B on deals, buybacks in next 3 years — although BD chief notes finding the right deal still 'very hard'

4 years ago

Continuing push beyond Covid-19 vaccines, Moderna partners with 'CAR-M' biotech on in vivo cancer cell therapies

4 years ago

Takeda kicks off JPM week with M&A — buying out another gamma/delta spinout and diving into a new ‘swim lane’

4 years ago

In $900M+ deal, rare disease biotechs team up on RNA therapies for CNS developmental disorders

4 years ago

Pfizer, the new master of mRNA delivery, teams up with Beam to ship base editors straight to target tissues

4 years ago

Bayer jumps on board Mammoth's ultra-small CRISPR tech with sights set first on the liver

4 years ago

Cytokinetics gets the Royalty treatment, snagging up to $450M to support closely watched heart programs

4 years ago

Merck revs up dealmaking engine ahead of #JPM22, inking collaborations with AI protein design player Absci

4 years ago

Regeneron hands off ex-US rights for cholesterol disorder drug to rare disease specialist Ultragenyx

4 years ago

Planting another flag on Pfizer and Alnylam's turf, AstraZeneca grabs amyloidosis drug from the biotech that invented Aduhelm

4 years ago

Sanofi, Exscientia ink the next AI megadeal, signing terms on a $100M upfront pact with up to 15 drugs on the line

4 years ago

Novartis is 'all in' on siRNA, inking a new collaboration with Alnylam to develop alternative to liver transplants

4 years ago

Merck KGaA beefs up its mRNA work with a $780M buyout of a booming player

4 years ago

Amgen partners with Flagship's machine learning startup, promising up to $1.9B as Big Pharma ups bet on AI

4 years ago

Gary Glick puts Odyssey's $218M cash stack to use, acquiring machine learning outfit

4 years ago

You know AAV and LNP. What about PLV? Eli Lilly lines up new vehicle to deliver its genetic medicines

4 years ago

BioNTech and Pfizer announce $225M shingles vaccine project, offering mRNA challenger to GlaxoSmithKline's Shingrix

4 years ago

Biogen bets $60M upfront that a new antisense candidate from Ionis can one-up Spinraza

4 years ago

Sutro strikes a $40M China deal as it looks to push ahead of a crowded pack

4 years ago

Novartis unwraps $1.5B gene therapy buyout — beefing up arsenal against retinal diseases

4 years ago

Pouncing on next-gen I/O play, Sanofi acquires Amunix for $1B+ and picks up 'universal mask' tech

4 years ago

First page Previous page 65 66 676869 70 71 Next page Last page